Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib.

Front Mol Biosci · 2026 · PMC13342395 · PMID 42422880

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Conclusion Higher EGFR VAF was significantly associated with improved overall survival in patients with EGFR-mutated NSCLC treated with first-line osimertinib and showed a numerical trend toward longer progression-free survival.

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.